A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.
The cholesterol-lowering drugs quell inflammation and reverse endothelial tissue damage, hints that they might curb the body’s excessive immune response to SARS-CoV-2 infection.
By studying influenza in mice and cells, researchers identify a glucose metabolism pathway critical to the dysregulated immune response that kills many infectious disease patients, including those with COVID-19.